<DOC>
	<DOCNO>NCT01987232</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose ass safety , tolerability activity carfilzomib give combination carboplatin etoposide initial therapy subject Extensive-Stage Small-Cell Lung Cancer ( ES SCLC ) .</brief_summary>
	<brief_title>Phase 1b/2 Study Carfilzomib , Carboplatin , Etoposide Subjects With Previously Untreated Extensive Stage Small-cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Key 1 . Histologically cytologically confirm diagnosis extensivestage smallcell lung cancer ( ESSCLC ) measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) Version 1.1 ; ESSCLC define : smallcell lung cancer ( SCLC ) spread beyond one hemithorax regional lymph node side ( e.g. , supraclavicular ) contralateral hemithorax , lymph node , distant location body 2 . Subjects asymptomatic brain metastasis central nervous system ( CNS ) disease screening/diagnosis eligible 3 . Males females â‰¥ 18 year age 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Key 1 . Previous systemic therapy treat smallcell lung cancer ( SCLC ) . Subjects recurrent progressive limitedstage SCLC previous systemic treatment eligible study participation . 2 . Whole brain focal radiation therapy within 14 day prior Cycle 1 Day 1 ( C1D1 ) Phase 1b prior randomization Phase 2 3 . Congestive heart failure ( New York Heart Association [ NYHA ] class III IV ) , symptomatic ischemia , conduction abnormality uncontrolled conventional intervention , myocardial infarction within 6 month prior prior C1D1 Phase 1b prior randomization Phase 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>